Cargando…
The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis
Background: Recently, immune checkpoint inhibitors (ICIs) have been proved one of the most promising anti-cancer therapy, series clinical trials have confirmed their efficacy. But they are also associated with distinctive set of toxic effects, which are recognized as immune-related adverse events. A...
Autores principales: | Ma, Ke, Lu, Yali, Jiang, Shanshan, Tang, Jiangong, Li, Xin, Zhang, Yuyang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297260/ https://www.ncbi.nlm.nih.gov/pubmed/30618738 http://dx.doi.org/10.3389/fphar.2018.01430 |
Ejemplares similares
-
Identification and prediction of immune checkpoint inhibitors-related pneumonitis by machine learning
por: Gong, Li, et al.
Publicado: (2023) -
Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis
por: Chen, Xinru, et al.
Publicado: (2020) -
Organ-Specific Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Monotherapy Versus Combination Therapy in Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Da, Lijun, et al.
Publicado: (2020) -
Advances in CT features and radiomics of checkpoint inhibitor-related pneumonitis: A short review
por: Huang, Jie, et al.
Publicado: (2023) -
Chronic immune checkpoint inhibitor pneumonitis
por: Naidoo, Jarushka, et al.
Publicado: (2020)